Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma

• Verfasst von: Hatiboglu, Gencay [VerfasserIn]
• Verfasst von: Pritsch, Maria [VerfasserIn]
• Verfasst von: Macher-Göppinger, Stephan [VerfasserIn]
• Verfasst von: Zöller, Margot [VerfasserIn]
• Verfasst von: Huber, Johannes [VerfasserIn]
• Verfasst von: Haferkamp, Axel [VerfasserIn]
• Verfasst von: Pahernik, Sascha [VerfasserIn]
• Verfasst von: Wagener, Nina [VerfasserIn]
• Verfasst von: Hohenfellner, Markus [VerfasserIn]
• Titel: Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma
• Verf.angabe: Gencay Hatiboglu, Maria Pritsch, Stephan Macher-Goeppinger, Margot Zöller, Johannes Huber, Axel Haferkamp, Sascha Pahernik, Nina Wagener & Markus Hohenfellner
• Jahr: 2013
• Umfang: 13 S.
• Fussnoten: Published online: 12 Nov 2012 ; Gesehen am 08.10.2021
• Titel Quelle: Enthalten in: Scandinavian journal of urology
• Ort Quelle: Abingdon : Taylor & Francis, 2013
• Jahr Quelle: 2013
• Band/Heft Quelle: 47(2013), 4, Seite 311-322
• ISSN Quelle: 2168-1813
• DOI: doi:10.3109/00365599.2012.740070
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: MAGE A9
• Sach-SW: prognostic marker
• Sach-SW: renal cell carcinoma
• K10plus-PPN: 1749526166

Abstract

Objective. The aim of this study was to evaluate the prognostic relevance of melanoma-associated antigen (MAGE) A9 in renal cell carcinoma (RCC). Material and methods. Immunohistochemical staining for MAGE A9 was evaluated in a tissue microarray containing 587 RCC tumour tissue samples. Nuclear MAGE A9 expression was reviewed using a semiquantitative score. Follow-up has been surveyed since 1990 in a prospectively conducted tumour database. The effect of MAGE A9 expression on cancer-specific survival (CSS) was assessed by univariate and multivariate Cox regression analyses. Subgroup analyses were performed for non-metastatic and metastatic disease. Results.Median age in all patients was 63.2 years, 354 patients were male and 233 female, and 108 patients had metastatic disease. Median follow-up was 5.6 years for all patients and 9.0 years for patients still alive (range 0-19.9 years). High nuclear MAGE A9 expression was present in 326 tumour specimens (55.5%). In multivariate analyses high nuclear MAGE A9 expression was associated with poor CSS (p = 0.0027). Furthermore, tumour stage, lymph-node and distant metastasis, Fuhrman grade G3/4, Karnofsky index < 80% and male gender were associated with poor CSS. In subgroup analyses, results were concordant for patients with non-metastatic disease. In patients with metastatic disease, only Karnofsky index > 80% was a significant predictor for CSS; MAGE A9 expression could not be shown to be associated with CSS (p = 0.161). Conclusions.High nuclear MAGE A9 expression is independently associated with poor CSS in patients with non-metastatic RCC. The assessment of MAGE A9 expression can provide additional prognostic information and should be used in decision-making regarding adjuvant therapy in patients with non-metastatic disease.